# Sutro Biopharma (STRO) — Earnings

STRO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/stro/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$1.40 |
| EPS estimate | −$3.82 |
| EPS surprise | +63.39% |
| Revenue surprise | +302.50% |
| Revenue | $63.7M |
| Revenue estimate | $15.8M |
| Reported | Aug 7, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1382101/000095017025105219/stro-20250630.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 7, 2025 | −$3.82 | −$1.40 | 63.39% | $15.8M | $63.7M |
| Q1 2025 | May 8, 2025 | −$6.43 | −$9.10 | -41.62% | $11.6M | $17.4M |
| Q4 2024 | Mar 13, 2025 | −$8.30 | −$8.30 | 0.05% | $12.2M | $14.8M |
| Q3 2024 | Nov 13, 2024 | −$7.35 | −$5.90 | 19.68% | $15.3M | $8.5M |
| Q2 2024 | Aug 13, 2024 | −$7.92 | −$5.90 | 25.47% | $21.0M | $25.7M |
| Q1 2024 | May 13, 2024 | −$9.22 | −$9.50 | -3.08% | $12.1M | $13.0M |
| Q4 2023 | Mar 25, 2024 | −$2.71 | $5.20 | 291.69% | $57.4M | $113.7M |
| Q3 2023 | Nov 13, 2023 | −$7.36 | −$8.10 | -10.05% | $13.0M | $16.9M |
| Q2 2023 | Aug 10, 2023 | −$7.33 | −$6.40 | 12.63% | $12.6M | $10.4M |
| Q1 2023 | May 15, 2023 | −$7.84 | −$8.50 | -8.45% | $12.1M | $12.7M |
| Q4 2022 | Mar 30, 2023 | −$6.21 | −$5.90 | 5.03% | $14.5M | $8.6M |
| Q3 2022 | Nov 8, 2022 | −$2.89 | −$3.70 | -28.14% | $35.7M | $25.1M |
| Q2 2022 | Aug 8, 2022 | −$6.44 | −$5.50 | 14.63% | $16.0M | $28.1M |
| Q1 2022 | May 9, 2022 | −$7.57 | −$8.40 | -10.90% | $10.5M | $5.9M |
| Q4 2021 | Feb 28, 2022 | −$7.59 | −$8.30 | -9.33% | $11.8M | $10.4M |
| Q3 2021 | Nov 10, 2021 | −$6.51 | −$6.70 | -2.87% | $9.0M | $8.5M |
| Q2 2021 | Aug 9, 2021 | −$4.14 | −$1.30 | 68.60% | $13.3M | $28.0M |
| Q1 2021 | May 7, 2021 | −$6.23 | −$6.60 | -5.88% | $4.8M | $14.7M |
| Q4 2020 | Mar 18, 2021 | −$5.70 | −$15.40 | -170.18% | $8.3M | $8.3M |
| Q3 2020 | Nov 5, 2020 | −$5.07 | $4.50 | 188.73% | $7.3M | $17.8M |

## Frequently Asked Questions

### When did Sutro Biopharma (STRO) last report earnings?

Sutro Biopharma last reported on Aug 7, 2025, covering fiscal Q2 2025.

### Did STRO beat earnings estimates?

Yes. Sutro Biopharma reported EPS of −$1.40 for Q2 2025 against a −$3.82 estimate — a 63.39% beat.

### How much revenue did STRO report last quarter?

Sutro Biopharma reported $63.7M in revenue for Q2 2025, against a consensus estimate of $15.8M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).